Global Study Links 1 in 8 Cancer Cases to Preventable Infections

Nearly one in eight cancer cases diagnosed worldwide are linked to infectious agents that can be treated, managed, or prevented entirely, according to a major study published in The Lancet Oncology. Researchers estimated that approximately 2.3 million new cancer diagnoses in 2024, representing 12% of the global total, were attributable to infections.

The findings underscore a profound disconnect between existing medical interventions and their global deployment, particularly as low- and middle-income regions shoulder the vast majority of this preventable burden. Experts emphasized that effective vaccines, screening protocols, and pharmaceutical treatments already exist for the primary infectious drivers identified in the analysis.

Leading Infectious Drivers of Global Cancer

The study identified five dominant pathogens responsible for the vast majority of infection-attributable malignancies. Helicobacter pylori and human papillomavirus together accounted for more than 1.5 million cases in 2024. Helicobacter pylori, a bacterial stomach infection spread through contaminated food, water, or saliva, was linked to roughly 760,000 cases, predominantly gastric cancers. Human papillomavirus, a sexually transmitted viral infection encompassing more than 100 strains, accounted for approximately 750,000 cases, primarily cervical cancers.

Additional major contributors included the hepatitis B virus, which was tied to 360,000 liver cancer cases, and the Epstein-Barr virus, associated with 260,000 cases largely driven by nasopharyngeal malignancies in the head and neck. The hepatitis C virus accounted for 160,000 liver cancer diagnoses. While infections such as Epstein-Barr virus and hepatitis B can remain asymptomatic for decades, chronic inflammation or viral persistence significantly elevates long-term oncological risks.

Global Disparities in Disease Burden

The global distribution of infection-related cancers reveals stark socioeconomic disparities. Low-income and middle-income nations accounted for 77% of all infection-attributable cancer cases recorded in the study. Researchers noted that Eastern Asia, Sub-Saharan Africa, and Southeast Asia experience the heaviest burdens, reflecting uneven access to clinical screening infrastructure, vaccination campaigns, and early-stage medical treatments.

The analysis includes additional infectious agents, such as HIV and Merkel cell polyomavirus, as well as newly established infection-cancer associations based on cancer burden estimates from the IARC Global Cancer Observatory database.

In the United States, infection-attributable cancers represent a smaller but notable share. A separate analysis cited by researchers indicated that approximately 3.4% of adult cancers in the U.S. in 2019 were linked to seven evaluated infections. Specialists stressed that having a cancer-causing infection does not guarantee malignancy, as disease development typically requires long-term persistence alongside genetic, environmental, and lifestyle factors.

Available Prevention and Treatment Tools

Study authors emphasized that clinical toolkits already exist to neutralize four of the five leading infectious cancer catalysts, alongside the human immunodeficiency virus. Highly effective vaccines protect against human papillomavirus and hepatitis B, while short courses of antiviral medications can cure hepatitis C, and standard antibiotic regimens can eradicate Helicobacter pylori.

Public health authorities have documented the tangible impact of these interventions. In the United States, introduction of the human papillomavirus vaccine Gardasil led to an 88% decrease in targeted viral infections among females aged 14 to 19 within 12 years. Furthermore, cervical precancer rates dropped by up to 50% among screened younger cohorts following vaccine rollout. Researchers argue that expanding vaccination coverage, routine viral testing, and safe injection practices globally could avert hundreds of thousands of future cancer diagnoses.

University of Birmingham tumor virologist Claire Shannon-Lowe explained that EBV's biological complexity and lifetime persistence have hindered vaccine development, but recent impetus from EBV's links to multiple sclerosis and lupus has brought a potential vaccine into sight for prevention and cancer treatment.

Implementation and Next Steps

Health officials face the challenge of translating existing scientific countermeasures into accessible public health programs worldwide. Researchers recommend that international bodies prioritize resource allocation toward regions with high infection prevalence and limited healthcare infrastructure. Continued epidemiological tracking and expanded screening initiatives remain central to mitigating the global infection-related cancer burden.

Preventable infection does not mean every cancer is preventable

When researchers attribute a share of cancers to infections, they are estimating the population-level contribution of particular pathogens under defined assumptions. It does not mean that one in eight individual patients could certainly have avoided cancer. Prevention can include vaccination, safer exposure, timely treatment of infections and appropriate screening, depending on the cancer type. The relevant local picture varies because infection prevalence and access to services differ widely. Readers should examine which organisms and cancer sites the estimate includes rather than treating a global fraction as the risk for one person.